全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

To Analyze the Sensitivity of RT-PCR Assays Employing S Gene Target Failure with Whole Genome Sequencing Data during Third Wave by SARS-CoV-2 Omicron Variant

DOI: 10.4236/aim.2024.145018, PP. 247-255

Keywords: SARS-CoV-2, S Gene Target Failure, Whole Genome Sequencing, Omicron

Full-Text   Cite this paper   Add to My Lib

Abstract:

Introduction: Omicron is a highly divergent variant of concern (VOCs) of a severe acute respiratory syndrome SARS-CoV-2. It carries a high number of mutations in its spike protein hence; it is more transmissible in the community by immune evasion mechanisms. Due to mutation within S gene, most Omicron variants have reported S gene target failure (SGTF) with some commercially available PCR kits. Such diagnostic features can be used as markers to screen Omicron. However, Whole Genome Sequencing (WGS) is the only gold standard approach to confirm novel microorganisms at genetically level as similar mutations can also be found in other variants that are circulating at low frequencies worldwide. This Retrospective study is aimed to assess RT-PCR sensitivity in the detection of S gene target failure in comparison with whole genome sequencing to detect variants of Omicron. Methods: We have analysed retrospective data of SARS-CoV-2 positive RT-PCR samples for S gene target failure (SGTF) with TaqPath COVID-19 RT-PCR Combo Kit (ThermoFisher) and combined with sequencing technologies to study the emerged pattern of SARS-CoV-2 variants during third wave at the tertiary care centre, Surat. Results: From the first day of December 2021 till the end of February 2022, a total of 321,803 diagnostic RT-PCR tests for SARS-CoV-2 were performed, of which 20,566 positive cases were reported at our tertiary care centre with an average cumulative positivity of 6.39% over a period of three months. In the month of December 21 samples characterized by the SGTF (70/129) were suggestive of being infected by the Omicron variant and identified as Omicron (B.1.1.529 lineage) when sequence. In the month of January, we analysed a subset of samples (n = 618) with SGTF (24%) and without SGTF (76%) with Ct values < 25 for N, ORF 1ab and S gene with sequencing. We found other sublineages namely BA.1, BA.1.1, and BA.2 as a result over a period of time. Finally in the month of February-22 BA.2 lineage emerged and BA.2 was the most predominant and found to be increasing each week. It was clearly observed that Omicron has spread in the community and within two months the proportion of pre-existing Delta variants became zero. Conclusions: During the COVID-19 pandemic, it took almost more than 15 days to diagnose infection and identify pathogen by sequencing technology. In contrast to that molecular assay provided quick identification with the help of SGTF phenomenon within 5 hours of duration. This strategy helps

References

[1]  Konyak, B.M., Sharma, M., Kharia, S., Pandey, R.P. and Chang, C.-M. (2022) A Systematic Review on the Emergence of Omicron Variant and Recent Advancement in Therapies. Vaccines, 10, Article 1468.
https://doi.org/10.3390/vaccines10091468
[2]  Esman, A., Cherkashina, A., Mironov, K., Dubodelov, D., Salamaikina, S., Golubeva, A., Gasanov, G., Khafizov, K., Petrova, N. and Cherkashin, E. (2022) SARS-CoV-2 Variants Monitoring Using Real-Time PCR. Diagnostics, 12, Article 2388.
https://doi.org/10.3390/diagnostics12102388
[3]  Guerrero-Preston, R., Rivera-Amill, V., Caraballo, K., Rodríguez-Torres, S., Purcell-Wiltz, A., García, A.A., Torres, R.S., Zamuner, F.T., Zanettini, C. and MacKay, M.J. (2022) Precision Health Diagnostic and Surveillance Network Uses S Gene Target Failure (SGTF) Combined with Sequencing Technologies to Track Emerging SARS-CoV-2 Variants. Immunity, Inflammation and Disease, 10, e634.
https://doi.org/10.1002/iid3.634
[4]  Gulzar, B., Rishi, S., Farhana, A., Sheikh, A.A. and Dewani, S. (2022) Clinico-Demographic Characteristics of Third Wave by Omicron (B. 1.1. 529) Variant of SARS-CoV-2 at a Tertiary Care Center, J & K India. Journal of Advanced Medical and Dental Sciences Research, 10, 5-9.
[5]  Subramoney, K., Mtileni, N., Bharuthram, A., Davis, A., Kalenga, B., Rikhotso, M., Maphahlele, M., Giandhari, J., Naidoo, Y. and Pillay, S. (2022) Identification of SARS-CoV-2 Omicron Variant Using Spike Gene Target Failure and Genotyping Assays, Gauteng, South Africa, 2021. Journal of medical virology, 94, 3676-3684.
https://doi.org/10.1002/jmv.27797
[6]  Doerre, A. and Doblhammer, G. (2022) The Influence of Gender on COVID-19 Infections and Mortality in Germany: Insights from Age-and Gender-Specific Modeling of Contact Rates, Infections, and Deaths in the Early Phase of the Pandemic. PLOS ONE, 17, e0268119.
https://doi.org/10.1371/journal.pone.0268119
[7]  Wolter, N., Jassat, W., Walaza, S., Welch, R., Moultrie, H., Groome, M., Amoako, D.G., Everatt, J., Bhiman, J.N. and Scheepers, C. (2022) Early Assessment of the Clinical Severity of the SARS-CoV-2 Omicron Variant in South Africa: A Data Linkage Study. The Lancet, 399, 437-446.
https://doi.org/10.1016/S0140-6736(22)00017-4
[8]  Kemp, S.A., Collier, D.A., Datir, R.P., Ferreira, I.A., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P. and Lumb, I.U. (2021) SARS-CoV-2 Evolution during Treatment of Chronic Infection. Nature, 592, 277-282.
[9]  Organization, W.H. (2021) Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern.
https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
[10]  Pulliam, J.R., Van Schalkwyk, C., Govender, N., Von Gottberg, A., Cohen, C., Groome, M.J., Dushoff, J., Mlisana, K. and Moultrie, H. (2022) Increased Risk of SARS-CoV-2 Reinfection Associated with Emergence of Omicron in South Africa. Science, 376, eabn4947.
https://doi.org/10.1126/science.abn4947
[11]  Viana, R., Moyo, S., Amoako, D.G., Tegally, H., Scheepers, C., Althaus, C.L., Anyaneji, U.J., Bester, P.A., Boni, M.F. and Chand, M. (2022) Rapid Epidemic Expansion of the SARS-CoV-2 Omicron Variant in Southern Africa. Nature, 603, 679-686.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133